Multiple Sclerosis Trial, Not Yet Recruiting NCT05415579 Sponsor: Dongzhimen Hospital, Beijing Condition: Multiple Sclerosis
Back to Multiple Sclerosis

Multiple Sclerosis Trial, Not Yet Recruiting

NCT05415579
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 18 to 65 years old, of any gender.
  • People who have been diagnosed with a demyelinating disease of the central nervous system, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), or myelin oligodendrocyte glycoprotein-associated disease (MOGAD), based on recognised diagnostic guidelines.
  • People who are currently receiving, or are willing to receive, Traditional Chinese Medicine (TCM) treatments, which may include Chinese herbal medicine, acupuncture, moxibustion, massage, tai chi, or qigong.
  • People who have provided written informed consent, either personally or through a legally authorised representative.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who decline to give their written informed consent to participate.
  • People who have cancer, infectious diseases (such as hepatitis B, hepatitis C, or HIV), serious immune system deficiencies (whether present from birth or developed over time), or significant heart, lung, or liver conditions.
  • People with a mental health condition or severe difficulty with thinking and memory that would make it hard to complete the information gathering and assessments required by the trial.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 17 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +86-10-84013209

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Dongzhimen Hospital, Beijing
Registry
ClinicalTrials.gov
Start date
20 June 2022
Est. completion
31 October 2029

Primary endpoints

Annualized Aggregate Relapse Rate (ARR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 17 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov